Brought to you by 
Genentech to use Vysis' HER-2 test
29 Apr 2020
Executive Summary
Genentech will use Vysis' (genetic testing; a division of BP Amoco) PathVysion fluorescent in situ hybridization (FISH) DNA test for the HER-2 gene to assess patients taking Herceptin (trastuzumab), and also in future clinical trials of the drug.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genentech to use Vysis' HER-2 test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice